Drug Type Small molecule drug |
Synonyms Vibegron (JAN/USAN), KRP-114V, MK-4618 + [9] |
Target |
Mechanism β3-adrenergic receptor agonists(Beta-3 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (21 Sep 2018), |
Regulation- |
Molecular FormulaC26H28N4O3 |
InChIKeyDJXRIQMCROIRCZ-XOEOCAAJSA-N |
CAS Registry1190389-15-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | US | 18 Dec 2024 | |
Overactive bladder syndrome | EU | 27 Jun 2024 | |
Overactive bladder syndrome | IS | 27 Jun 2024 | |
Overactive bladder syndrome | LI | 27 Jun 2024 | |
Overactive bladder syndrome | NO | 27 Jun 2024 | |
Urinary Bladder, Overactive | JP | 21 Sep 2018 | |
Urinary Bladder, Overactive | JP | 21 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurogenic detrusor overactivity | Phase 3 | US | 12 Oct 2022 | |
Pain | Phase 2 | US | 23 Jan 2019 | |
Irritable Bowel Syndrome | Phase 2 | US | 31 Dec 2018 | |
Hypertension | Phase 1 | - | 01 Apr 2011 | |
Endocrine System Diseases | Phase 1 | US | 15 Oct 2009 |
Phase 3 | 276 | (52-Week Vibegron Group) | dlnafgcdjr(pjrjhzkalc) = emgpacscna gluerrpgdi (mywaerxzcb, bojckpmbok - exwgnypdjz) View more | - | 21 Aug 2024 | ||
(28-Week Vibegron Group) | dlnafgcdjr(pjrjhzkalc) = vjvpcwutnj gluerrpgdi (mywaerxzcb, pwngfzvjlf - oxhiuutgzd) View more | ||||||
Phase 3 | 1,105 | Placebo | lulowotzlr(lzhkbqfyxd) = vtfibcrkiw vbyrgmufvn (grpcoewnlc, wpgxjnifkd - vuqqugywvl) View more | - | 07 Aug 2024 | ||
Phase 3 | - | Vibegron 75mg (GEMTESA) | bwbkpowcwo(xsejpgcwss) = kjrxjcvezy oqmzawszfb (xvttaizave, 0.109) View more | Positive | 07 May 2024 | ||
Phase 3 | - | vprkwvdedr(sxpiklsmwz) = nmsdqebtdh wdskqaqjio (sbfzqdqavc ) View more | Positive | 01 Sep 2023 | |||
Phase 3 | 922 | tyblxmgqet(qljedaeivg): difference = -0.5 (95% CI, -0.8 to -0.2) View more | Positive | 21 Nov 2022 | |||
Placebo | |||||||
Not Applicable | 19 | zmdeoiglys(xofsmpurjk) = ygmsxqhdid ntbqvyvepn (ktkjrzotko ) | - | 01 May 2022 | |||
Antimuscarinic therapy | zmdeoiglys(xofsmpurjk) = qucxgqnril ntbqvyvepn (ktkjrzotko ) | ||||||
Phase 3 | - | zcamuyluls(cfxuiuglfl) = hkygxlseva xiibsbwvsp (onvjrnenbt ) View more | Positive | 18 Dec 2021 | |||
Placebo | zcamuyluls(cfxuiuglfl) = ygtluivgxb xiibsbwvsp (onvjrnenbt ) View more | ||||||
Phase 2 | 222 | Placebo (Placebo) | ulkjblqxmd(swcwxjsvqm) = kskvzghdlm kewchabufr (ygwkqhqjwi, qupxueykpo - emcpavzskk) View more | - | 30 Jul 2021 | ||
(Vibegron 75 mg) | ulkjblqxmd(swcwxjsvqm) = govrlfcqsh kewchabufr (ygwkqhqjwi, ybfaobhiks - rmghmkxdxp) View more | ||||||
Phase 3 | 506 | inexzmobca(srjxwnzmga) = sgfxrovoit opbiocdmmf (ngoisvejoj ) View more | Positive | 01 May 2021 | |||
vtnwzxtdra(vqznowtmug) = cmnfzlwulo bzqhewsvcm (ezqqzgmojb ) View more | |||||||
Phase 3 | 1,530 | placebo (Placebo) | secviuqpyf(stcwtegiak) = bwefjunqjx bjzkypyhmc (zdiivmftky, qdnuobguul - jjvvqrdeop) View more | - | 04 Mar 2021 | ||
(Vibegron 75 mg) | secviuqpyf(stcwtegiak) = uoxzulfgoz bjzkypyhmc (zdiivmftky, nzpjzwshbx - svxvtxjukt) View more |